Body composition after endogenous (Cushing's syndrome) and exogenous (rheumatoid arthritis) exposure to glucocorticoids

Hormone and Metabolic Research

Volumn 42, Issue 8, 2010, Pages 613-618

  Resmini, E ^a   Farkas, C ^a   Murillo, B ^a   Barahona, M J ^a,b   Santos, A ^a   Martnez Momblan M A ^a   Roig, O ^a   Ybarra, J ^a   Geli, C ^c   Webb, S M ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c Hospital Sant Pau   (Spain)

Author keywords

body composition; Cushing's syndrome; glucocorticoids; rheumatoid arthritis

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; PREDNISONE; ESTROGEN; GROWTH HORMONE;

ADRENAL INSUFFICIENCY; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DENSITY; CONTROLLED STUDY; CUSHING SYNDROME; DISEASE DURATION; DRUG EXPOSURE; ESTROGEN DEFICIENCY; FEMALE; HUMAN; HYPERCORTISOLISM; LEAN BODY WEIGHT; LONG TERM EXPOSURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; WAIST HIP RATIO; ARTHRITIS, RHEUMATOID; CASE CONTROL STUDY; DEFICIENCY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARTHRITIS, RHEUMATOID; BODY COMPOSITION; CASE-CONTROL STUDIES; CUSHING SYNDROME; ESTROGENS; FEMALE; GLUCOCORTICOIDS; GROWTH HORMONE; HUMANS; MIDDLE AGED;

EID: 77954233206     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1255032     Document Type: Article

References (32)

1. Burt MG, Gibney J, Ho KK. Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clin Endocrinol 2006 64 436-443
2. Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin N Am 2005 34 341-356
3. Fernandez-Rodriguez E, Stewart PM, Cooper MS. The pituitary-adrenal axis and body composition. Pituitary 2009 12 105-115
4. Niu CS, Yeh CH, Yeh MF, Cheng JT. Increase of adipogenesis by ginsenoside (Rh2) in 3T3-L1 cell via an activation of glucocorticoid receptor. Horm Metab Res 2009 41 271-276
5. Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP, Besser GM, Grossman AB, Reznek RH. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol 2003 149 561-567
6. Ueland T, Kristo C, Godang K, Aukrust P, Bollerslev J. Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: a longitudinal study. J Clin Endocrinol Metab 2003 88 1492-1496
7. Pirlich M, Biering H, Gerl H, Ventz M, Schmidt B, Ertl S, Lochs H. Loss of body cell mass in Cushing's syndrome: Effect of treatment. J Clin Endocrinol Metab 2002 87 1078-1084
8. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G. Persistence of increased cardiovascular risk in patients with Cushing's disease after 5 years of successful cure. J Clin Endocrinol Metab 1999 84 2664-2672
9. Lewis JG, Borowski KK, Shand BI, George PM, Scott RS. Plasma sex hormone-binding globulin, corticosteroid-binding globulin, cortisol, and free cortisol levels in outpatients attending a lipid disorders clinic: a cross-sectional study of 1137 subjects. Horm Metab Res 2010 42 274-279
10. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med 2007 120 936-939
11. Boland EW, Headley NE. Results of long-continued cortisone administration in rheumatoid arthritis. Calif Med 1975 74 416-423
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchel DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT. The American Rheumatism association 1987. Revised criteria for the classification of Rheumatoid Arthritis. Arthritis Rheum 1988 31 315-323
13. Wilson TA, Blizzard RM. Adrenal insufficiency in childhood. In: Lavin N (ed.) Manual of Endocrinology and Metabolism. Boston Little, Brown & Co 1986 189
14. Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary 2004 7 253-256
15. Albiger N, Testa RM, Almoto B, Ferrari M, Bilora F, Petrobelli F, Pagnan A, Mantero F, Scaroni C. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006 38 405-410
16. Huxley R, Mendis S, Zheleznyakov E, Reddy S, Chan J. Body mass index, waist circumference and waist-hip ratio as predictors of cardiovascular risk-a review of the literature. Eur J Clin Nutr 2010 64 16-22
17. Barahona MJ, Sucunza N, Resmini E, Fernández-Real JM, Ricart W, Moreno-Navarrete JM, Puig T, Farrerons J, Webb SM. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab 2009 94 3365-3371
18. Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP, Nieman LK. The effects of child-and adolescent-onset endogenous Cushing syndrome on bone mass, body composition and growth: a 7-year prospective study into young adulthood. J Bone Miner Res 2007 22 110-118
19. Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin N Am 2005 34 327-339
20. Stewart PM. Tissue-specific Cushing's syndrome, 11-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrin 2003 149 163-168
21. Tomlinson JW, Walker EA, Bujalska IJ. 11-Hydroxysteroid Dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. End Rev 2004 25 831-866
22. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect Cushing's disease of the omentum? The Lancet 1997 349 1210-1213
23. Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrin and target tissue-related causes. Int J Obes 2000 24 50-55
24. Kola B, Christ-Crain M, Lolli F, Arnaldi G, Giacchetti G, Boscaro M, Grossman AB, Korbonits M. Changes in AMP-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome. J Clin Endocrinol Metab 2008 93 4969-4973
25. Pecori Giraldi F, Andrioli M, De Marinis L, Bianchi A, Giampietro A, De Martin M, Sacco E, Scacchi M, Pontecorvi A, Cavagnini F. Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease. Eur J Endocrinol 2007 156 233-239
26. Burt MG, Gibney J, Ho KK. Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clin Endocrinol (Oxf) 2006 64 436-443
27. Webb SM, Mo D, Lamberts SW, Melmed S, Cavagnini F, Pecori Giraldi F, Strasburger CJ, Zimmermann AG, Woodmansee WW. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab 2010 95 630-638
28. McLeod KM, Johnson CS. Identifying women with low bone mass: a systematic review of screening tools. Geriatr Nurs 2009 30 164-173
29. Sherk VD, Palmer IJ, Bemben MG, Bemben DA. Relationships between body composition, muscular strength, and bone mineral density in estrogen-deficient postmenopausal women. J Clin Densitom 2009 12 292-298
30. Barahona MJ, Sucunza N, Resmini E, Fernández-Real J, Ricart W, Moreno J, Puig T, Wägner A, Rodriguez-Espinosa J, Farrerons J, Webb S. Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. J Bone Miner Res 2009 24 1841-1846
31. Kanazawa I, Yamaguchi T, Yano S, Hayashi K, Yamauchi M, Sugimoto T. Inhibition of the mevalonate pathway rescues the dexamethasone-induced suppression of the mineralization in osteoblasts via enhancing bone morphogenetic protein-2 signal. Horm Metab Res 2009 41 612-616
32. Westhovens R, Nijs J, Taelman V, Dequeker J. Body composition in rheumatoid arthritis. Br J Rheumatol 1997 36 444-448